Emergency medicine: magnesium sulphate injections and their pharmaceutical quality concerns

• Main Authors: Angus Nnamdi Oli, Ezinne Janefrances Nwankwo, Chukwuebuka Emmanuel Umeyor, Ugochukwu Stanley Umeh, Jude Nnaemeka Okoyeh, Chijioke M. Ofomata, Chukwuemeka Chukwubuikem Okoro, Emmanuel Chinedum Otakagu, Ruth Asikiya Afunwa, Gordon C. Ibeanu
• Format: Article
• Language: English
• Published: Elsevier 2021-05-01
• Series: Heliyon
• Subjects: Magnesium sulphate; Women's health; Pre-eclampsia; Eclampsia; Quality drugs
• Online Access: http://www.sciencedirect.com/science/article/pii/S2405844021012020

Objectives: World Health Organization has recognized magnesium sulphate as the drug of choice for prevention and treatment of fits associated with preeclampsia and eclampsia which are amongst the leading causes of maternal morbidity and mortality. In this study, the pharmaceutical quality of magnesium sulphate injections marketed in Anambra state was assessed. Methods: Ninety samples of magnesium sulphate obtained from the 3 senatorial zones in Anambra state were subjected to identification tests, microbiological analysis consisting of Growth promotion test, sterility and endotoxin test. Content analysis using titrimetric method and pH analysis were also carried out on the samples. Results: Twenty percent (20%) of samples obtained from Onitsha failed identification test as they had no Registration number in Nigeria. All samples subjected to the microbiology tests (sterility and endotoxin test) passed. Twenty percent (20%) and thirty-three percent (33.3%) of samples sourced from Onitsha and Nnewi respectively failed the pH analysis test. All the samples passed microbiological tests and had their Active Pharmaceutical Ingredients (API) within the acceptable limit. Conclusions: This study reveals that there are still some substandard magnesium sulphate injections in circulation in the locality. The supply chain of these drugs should be monitored to ensure a reduction in the incidences of substandard magnesium sulphate and positive therapeutic outcome which translates to reduced maternal mortality associated with pre-eclampsia and eclampsia in Nigeria.